SCHEMBL487779

SCHEMBL487779

O=C(O)CCCc1ccccc1N1C(=O)C=CC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 7/20 0.57
TLR9 Q9NR96 2/20 0.48
HDAC3 O15379 1/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
HDAC4 P56524 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HDAC1 Q13547 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
ALDH1A1 P00352 1/20 0.46
HSP90AA1 P07900 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28418862 0.94 MGLL (0.54) MGLLTLR9HDAC3HDAC4HDAC1
SCHEMBL5717701 0.83 NR1H3 (0.63) HDAC3MAPK1ADRA1AHDAC4SLC6A3
SCHEMBL722567 0.82 MGLL (0.51) MGLLTLR9HDAC3HDAC1HDAC2
Hydrochloric Acid SCHEMBL562848 0.81 MGLL (0.50) MGLLTLR9HDAC3HDAC1HDAC2
SCHEMBL8352899 0.81 MGLL (0.77) MGLLTLR9ALDH1A1HSP90AA1PKM
SCHEMBL4957966 0.80 MGLL (0.65) MGLLTLR9ALDH1A1HSP90AA1PKM
SCHEMBL8612834 0.79 MGLL (0.59) MGLLTLR9ALDH1A1HSP90AA1PKM
SCHEMBL3873448 0.79 MGLL (0.73) MGLLTLR9ALDH1A1NR1H2NR1H3
SCHEMBL28019596 0.78 MEN1 (0.37) MGLLTLR9HDAC3MAPK1ADRA1A
SCHEMBL3879458 0.78 MGLL (0.71) MGLLTLR9ALDH1A1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2410991-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (an Ohio Corporation ) (US) 2012-02-01 EP claimed
EP-0895082-B1 Bubble jet method for spotting probes on a solid support and method of manufacturing probe arrays. CANON KK (JP) 2003-09-24 EP claimed
EP-3270954-A1 A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST Amal Therapeutics SA (CH) 2018-01-24 EP disclosed
EP-3270955-A1 A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER Amal Therapeutics SA (CH) 2018-01-24 EP disclosed
EP-2406630-B1 IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT SIEMENS HEALTHCARE DIAGNOSTICS INC (US) 2018-01-17 EP disclosed
US-9720004-B2 Immunoassays employing non-particulate chemiluminescent reagent SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2017-08-01 US disclosed
WO-2016146262-A1 A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER AMAL THERAPEUTICS SA (CH) 2016-09-22 WO disclosed
WO-2016146143-A1 CELL PENETRATING PEPTIDES AND COMPLEXES COMPRISING THE SAME AMAL THERAPEUTICS SA (CH) 2016-09-22 WO disclosed
WO-2016146260-A1 A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST AMAL THERAPEUTICS SA (CH) 2016-09-22 WO disclosed
CN-105960265-A Method for treating wound healing using chemically modified oligonucleotides 阿克赛医药公司 2016-09-21 CN disclosed
US-20160231336-A1 IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2016-08-11 US disclosed
CN-102348980-B Immunoassays employing non-particulate chemiluminescent reagent SIEMENS HEALTHCARE DIAGNOSTICS 2015-05-27 CN disclosed
WO-2011041003-A9 COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS WYETH LLC (US) 2011-06-09 WO disclosed
WO-2011041003-A2 COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS WYETH LLC (US) 2011-04-07 WO disclosed
WO-2010104683-A1 IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2010-09-16 WO disclosed
US-5686071-A Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease PER IMMUNE HOLDINGS, INC. (US) 1997-11-11 US disclosed
WO-1996039124-A1 POLYMER AFFINITY SYSTEMS FOR THE DELIVERY OF CYTOTOXIC MATERIALS AND OTHER COMPOUNDS TO SITES OF DISEASE AKZO NOBEL N.V. (NL) 1996-12-12 WO disclosed
US-4536391-A REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT OTSUKA PHARMACEUTICAL CO. (JP) 1985-08-20 US disclosed
EP-0109653-A2 Process for preparing urokinase complex OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-05-30 EP disclosed